Recent publicity around the use of new antiobesity medications (AOMs) has focused the attention of patients and healthcare providers on the role of pharmacotherapy in the treatment of obesity. Newer drug treatments have shown greater efficacy and safety compared with older drug treatments, yet access to these drug treatments is limited by providers’ discomfort in prescribing, bias, and stigma around obesity, as well as by the lack of insurance coverage. Now more than ever, healthcare providers must be able to discuss the risks and benefits of the full range of antiobesity medications available to patients, and to incorporate both guideline based advice and emerging real world clinical evidence into daily clinical practice. The tremendous variability in response to antiobesity medications means that clinicians need to use a flexible approach that takes advantage of specific features of the antiobesity medication selected to provide the best option for individual patients. Future research is needed on how best to use available drug treatments in real world practice settings, the potential role of combination therapies, and the cost effectiveness of antiobesity medications. Several new drug treatments are being evaluated in ongoing clinical trials, suggesting that the future for pharmacotherapy of obesity is bright.

中文翻译：

---

肥胖药物的有效性和安全性

最近有关新型抗肥胖药物 (AOM) 使用的宣传将患者和医疗保健提供者的注意力集中在药物治疗在肥胖治疗中的作用。与旧的药物治疗相比，新的药物治疗显示出更高的疗效和安全性，但由于提供者在处方方面的不适、偏见和肥胖的耻辱以及缺乏保险覆盖，获得这些药物治疗的机会受到限制。现在，医疗保健提供者比以往任何时候都更必须能够讨论患者可用的各种抗肥胖药物的风险和益处，并将基于指南的建议和新兴的现实世界临床证据纳入日常临床实践。对抗肥胖药物的反应存在巨大差异，这意味着临床医生需要采用灵活的方法，利用所选抗肥胖药物的特定特征，为个体患者提供最佳选择。未来需要研究如何在现实世界的实践环境中最好地使用现有的药物治疗、联合疗法的潜在作用以及抗肥胖药物的成本效益。正在进行的临床试验正在评估几种新的药物治疗方法，这表明肥胖药物治疗的前景是光明的。